Boston Scientific Corp. wins 510(k) clearance from the Food & Drug Administration for its new Acuity Break-Away lead delivery system for cardiac resynchronization therapy devices.
Boston Scientific Corp. (NYSE:BSX) won 510(k) clearance from the Food & Drug Administration for a new lead delivery system for its cardiac resynchronization therapy devices.
The device is designed to reduce the risks associated with implanting CRT device leads, the wires that conduct electrical signals via blood vessels from a pacemaker or defibrillator into the heart.
Covidien champions positive results for the Barrett's esophagus ablation device it acquired along...
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48,...
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...